Finance1 min read

Five pharma CDMO stocks with robust revenue growth in Q2FY27

By · Published by Everything Blog

In short

Strong performance in the sector was highlighted by Blue Jet Healthcare, which achieved a 127.1% year-on-year revenue surge to ₹3,757 million on normalized customer inventory cycles and renewed demand in chronic therapies. Acutaas Chemicals also logged substantial expansion, driven by its advanced intermediate vertical and over 25% volume growth in generic intermediates. Both firms are reinforcing their operating models through long-term capital projects and strategic shifts away from lower-margin chemical commodities.

Key points

  • Global pharmaceutical firms are actively diversifying supply chains and cutting costs by…: Global pharmaceutical firms are actively diversifying supply chains and cutting costs by outsourcing research and production contracts.
  • Acutaas Chemicals is strategically phasing out lower-margin commodity chemicals to priori…: Acutaas Chemicals is strategically phasing out lower-margin commodity chemicals to prioritize its expanding contract development platform.
  • Blue Jet Healthcare is investing in long-term manufacturing infrastructure, including a ₹…: Blue Jet Healthcare is investing in long-term manufacturing infrastructure, including a ₹2,500 million backward integration facility at Mahad Unit 3.

Sources checked by our analysis pipeline: 1

Global pharmaceutical companies are increasingly outsourcing research and manufacturing to diversify supply chains and lower costs.

Indian contract development and manufacturing organisations (CDMOs) have emerged as key beneficiaries, moving up the value chain into complex custom synthesis, peptides, and specialty intermediates.

While broader pharmaceutical earnings remained mixed in the September 2026 quarter, select CDMO stocks stood out with strong commercial scale-up and delivered robust revenue growth in Q2FY27. Take a look.

Blue Jet Healthcare is a speciality pharmaceutical CDMO engaged in developing and manufacturing advanced intermediates, APIs and high-intensity sweeteners.

Its business spans three segments: Contrast Media Intermediates for CT, X-ray and MRI imaging agents; Pharma Intermediates & APIs catering to chronic therapies such as CVS, oncology and CNS; and High-Intensity Sweeteners, including saccharin, supplied to global food, beverage and oral care companies.

Blue Jet Healthcare reported revenue of ₹3,757 m, up 127.1% YoY and 28.2% QoQ, while net profit increased 96.6% YoY and 31.0% QoQ to ₹1,025 m.

The exceptional quarterly performance was driven by a massive turnaround and expansion in the Pharma Intermediates & API vertical, which grew…

Finance